Table 4.
Comparison of clinical and demographical characteristics of patients according to presence of complications at first post-COVID-19 visit.
| Complication at first post-COVID-19 visit | p | ||
|---|---|---|---|
| Yes | No | ||
| Gender, n(%) | |||
| Male | 10 (50.0) | 52 (43.3) | 0.578a |
| Female | 10 (50.0) | 68 (56.7) | |
| Eye laterality, n(%) | |||
| Right | 11 (55.0) | 69 (57.5) | 0.834a |
| Left | 9 (45.0) | 51 (42.5) | |
| Fellow eye, n(%) | |||
| Drusen | 14 (70.0) | 75 (62.5) | 0.883b |
| Disciform scar | 4 (20.0) | 28 (23.3) | |
| Macular NV | 2 (10.0) | 17 (14.2) | |
| Initial nAMD type, n(%) | |||
| Type-1 | 15(75) | 84(70) | 0.858b |
| Type-2 | 4(20) | 23(19,2) | |
| Mixt | 1(5) | 13(10,8) | |
| Initial treatment, n(%) | |||
| Aflibercept | 9(45) | 79(65,8) | 0.002 b |
| Ranibizumab | 1(5) | 24(20) | |
| Bevacizumab | 10(50) | 17(14,2) | |
| Intravitreal injection at last 6 months, n(%) | |||
| Yes | 20(100) | 84(70) | 0.004 a |
| No | 0(0) | 36(30) | |
| Three intravitreal loading injections, n(%) | |||
| Yes | 10(50) | 115(95,8) | 0.001 c |
| No | 10(50) | 5(4,2) | |
| Age (years), mean ± SD (min-max) | 68.2 ± 8.7 (55–85) | 72.7 ± 8.7 (55–92) | 0.064d |
| Follow-up duration (months), mean ± SD (min-max) | 11.9 ± 14.8 (3–60) | 26.3 ± 14.5 (5–83) | 0.001 e |
| Baseline BCVA (ETDRS letters), mean ± SD (min-max) | 38.2 ± 23.1 (5–70) | 42.8 ± 25.7 (5–83) | 0.493e |
| BCVA at last pre-COVID-19 visit (ETDRS letters), mean ± SD (min-max) | 51.1 ± 22.5 (5–83) | 50.1 ± 23.9 (5–85) | 0.900e |
| Baseline CST (µm), mean ± SD (min-max) | 345.5 ± 30.4 (289–404) | 345.1 ± 34.4 (285–466) | 0.956d |
| CST at last pre-COVID-19 visit (µm), mean ± SD (min-max) | 294.3 ± 25.8 (246–328) | 281.9 ± 26.1 (218–345) | 0.051d |
| Total number of control visits, mean ± SD (min-max) | 8.7 ± 10.3 (2–40) | 17.4 ± 9.2 (2–57) | 0.001 e |
| Total number of intravitreal injections, mean ± SD (min-max) | 5.5 ± 4.9 (2–20) | 9.0 ± 4.9 (2–27) | 0.001 e |
| Total number of intravitreal injections at last 6 months, mean ± SD (min-max) | 2.8 ± 1.5 (1–6) | 1.6 ± 1.2 (0–5) | 0.007 e |
| Pre-COVID-19 injection interval (weeks), mean ± SD (min-max) | 7.5 ± 2.8 (4–13) | 12.3 ± 5.2 (5–28) | 0.001 e |
| Duration between last pre-COVID-19 and first post-COVID-19 intravitreal injection (weeks), mean ± SD (min-max) | 25.2 ± 5.9 (12–32) | 30.1 ± 14.9 (12–64) | 0.769e |
| Pre-COVID-19 visit interval (weeks), mean ± SD (min-max) | 5.1 ± 1.4 (4–8) | 6.1 ± 1.6 (4–12) | 0.005 e |
| Duration between last pre-COVID-19 and first post-COVID-19 follow-up visit (weeks), mean ± SD (min-max) | 23.8 ± 6.9 (12–32) | 18.9 ± 4.9 (12–32) | 0.001 e |
n = Number of Patients, SD = Standard Deviation, BCVA = Best Corrected Visual Acuity, CST = Central subfoveal thickness, NV = Neovascularisation.
a
Pearson Chi-Square Test, bFisher Freeman Halton Test, cFisher’s Exact Test, dStudent-t Test, eMann Whitney U Test.
p<0.05 accepted as statistically significant. (Statistically significant values denoted in bold)